002868.SZ
绿康生化
SZSE · Healthcare · C 制造业 · CN
CNY 21.57
−2.35%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 502.9M | 516.6M | 649.4M | 507.0M | 329.9M |
| Cost of Revenue | 446.8M | 482.0M | 703.7M | 552.4M | 339.1M |
| Gross Profit | 56.1M | 34.6M | (54.3M) | (45.4M) | (9.3M) |
| Operating Expenses | |||||
| R&D Expense | 21.4M | 25.6M | 35.6M | 27.5M | 21.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 45.8M | 55.4M | 45.5M | 38.1M | 27.3M |
| Selling & Marketing Expense | 12.6M | 14.0M | 15.5M | 15.9M | 10.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 137.7M | 156.3M | 163.5M | 124.4M | 78.0M |
| Cost and Expenses | 584.6M | 638.3M | 867.2M | 676.9M | 417.1M |
| Operating Income (EBIT) | (92.1M) | (128.4M) | (428.0M) | (236.1M) | (133.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (102.6M) | (138.9M) | (428.1M) | (240.9M) | (134.1M) |
| Income Tax Expense | 1.5M | 453.8K | 17.8M | (18.3M) | (11.4M) |
| Bottom Line | |||||
| Net Income | (103.7M) | (139.3M) | (444.9M) | (221.8M) | (121.9M) |
| Earnings from Cont. Ops | (2.3M) | (1.8M) | (87.7M) | (222.6M) | (122.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (103.7M) | (139.3M) | (444.9M) | (221.8M) | (121.9M) |
| Per Share | |||||
| Basic EPS | (CN¥0.67) | (CN¥0.90) | (CN¥2.86) | (CN¥1.44) | (CN¥0.79) |
| Diluted EPS | (CN¥0.67) | (CN¥0.90) | (CN¥2.86) | (CN¥1.44) | (CN¥0.79) |
| Revenue Per Share | CN¥3.29 | CN¥3.34 | CN¥4.17 | CN¥3.29 | CN¥2.14 |
| Shares | |||||
| Basic Shares Outstanding | 152.7M | 154.7M | 155.5M | 154.0M | 154.4M |
| Diluted Shares Outstanding | 152.7M | 154.7M | 155.5M | 154.0M | 154.4M |
| Profitability Metrics | |||||
| EBITDA | — | (30.7M) | (329.6M) | (166.8M) | (69.5M) |
| D&A | — | 97.7M | 98.4M | 69.3M | 64.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026